FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average burden									

0.5

hours per response:

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(h)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* MUELLER PETER					<u>V</u>	2. Issuer Name and Ticker or Trading Symbol VERTEX PHARMACEUTICALS INC / MA [VRTX]									all appli Directo	cable) or	g Pers	son(s) to Iss 10% Ow	/ner
(Last) (First) (Middle)						THE [VIIA]									below)	(give title VP Globa	1 R&	Other (s below)	pecify
	RTEX PHA ORATED	ARMACEUTICA	LS			Date of /15/20		est Trar	nsaction	(Mon	th/Day/Year)					vi Globa	i ito	D, C50	
130 WAVERLY STREET						4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)					
(Street) CAMBRIDGE MA 02139													X Form filed by One Reporting Person Form filed by More than One Reporting Person						
(City)	(\$	State)	(Zip)																
		Tab	le I - N	lon-Deri	vative	Sec	uriti	ies Ad	quire	d, D	isposed o	of, or B	eneficia	ally	Owned	i			
1. Title of Security (Instr. 3) 2. Transactic Date (Month/Day/				Execu Year) if any		Deemed cution Date, ny nth/Day/Year)				s Acquired f (D) (Insti	d (A) or r. 3, 4 and 5	nd 5) Securi Benefi Owned		es ially Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership		
									Code	v	Amount	(A) or (D)	Price		Reporte Transac (Instr. 3	tion(s)			Instr. 4)
Common Stock 06/15/20					2009)09					2,400	A	\$9.69	9	119,274			D	
Common Stock			06/15/2009				S ⁽¹⁾		2,400	D	\$31.020	.02(2)(3)		116,874		D			
Common Stock												3,882		882		I 4	401(k)		
		T	able I								posed of , converti				wned				
1. Title of Derivative Security (Instr. 3)	3. Transaction Date (Month/Day/Year)	Execution Date, r) if any			Transaction Code (Instr.		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		Exerc tion Day/\day/\day		7. Title and Amount of Securities Underlying Derivative Secu (Instr. 3 and 4)		De Se (Ir	3. Price of Derivative Security Instr. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	ly C	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercis	sable	Expiration Date	Title	Amount or Number of Shares						

Explanation of Responses:

1. Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1.

06/15/2009

- $2. Open \ market \ sales \ reported \ on \ this \ line \ occurred \ at \ a \ weighted \ average \ price \ of \ \$31.02 \ (range \ \$30.79 \ to \ \$31.40).$
- 3. Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

2,400

(4)

4. Fully vested.

Remarks:

Option

Kenneth S. Boger, Attorney-In-06/16/2009

2,400

Fact

03/16/2014

** Signature of Reporting Person

Date

2,400

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.